Advanced search
Publication Cover
Expert Opinion on Drug Metabolism & Toxicology Volume 12, 2016 - Issue 7
Submit an article Journal homepage
418
Views
4
CrossRef citations to date
0
Altmetric
Drug Evaluation

Pharmacodynamic assessment of vedolizumab for the treatment of ulcerative colitis

Leon P. McLeanDepartment of Medicine, Division of Gastroenterology and Hepatology, University of Maryland, Baltimore, MD, USA
&
Raymond K. CrossDepartment of Medicine, Division of Gastroenterology and Hepatology, University of Maryland, Baltimore, MD, USACorrespondence[email protected]
Pages 833-842 | Received 15 Jan 2016, Accepted 18 Apr 2016, Published online: 12 May 2016

Citations (4)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Renáta Bor, Anna Fábián, Mária Matuz, Zoltán Szepes, Klaudia Farkas, Pál Miheller, Tamás Szamosi, Áron Vincze, Mariann Rutka, Kata Szántó, Anita Bálint, Ferenc Nagy, Ágnes Milassin, Tibor Tóth, Ferenc Zsigmond, Judit Bajor, Katalin Müllner, Lilla Lakner, Mária Papp, Ágnes Salamon, Gábor Horváth, Krisztina Sarang, Eszter Schäfer, Patrícia Sarlós, Károly Palatka & Tamás Molnár. (2020) Real-life efficacy of vedolizumab on endoscopic healing in inflammatory bowel disease – A nationwide Hungarian cohort study. Expert Opinion on Biological Therapy 20:2, pages 205-213.
Read now

Articles from other publishers (3)

Jing YanAiling LiuLiang FangJun WuXueli DingYonghong Xu. (2023) The ulcerative colitis endoscopic index of severity score is superior to reflecting long-term prognosis in ulcerative colitis patients treated with vedolizumab. Medicine 102:44, pages e35799.
Crossref
Deloshaan Subhaharan, Pradeep K. Ramaswamy, Sewwandi Francisco & Naveed Ishaq. (2022) Vedolizumab-Induced Acute Interstitial Nephritis in Ulcerative Colitis. ACG Case Reports Journal 9:6, pages e00788.
Crossref
Timothy Wyant, Lili Yang & Maria Rosario. (2020) Comparison of the ELISA and ECL Assay for Vedolizumab Anti-drug Antibodies: Assessing the Impact on Pharmacokinetics and Safety Outcomes of the Phase 3 GEMINI Trials. The AAPS Journal 23:1.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.